Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST)

August 19, 2025 7:01 AM EDT Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $15.00 price target on Aquestive Therapeutics (NASDAQ: AQST).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login